Lakefront Biotherapeutics NV current report, Q4 FY2016

Business Context and Reporting Period

This Form 6-K filing is submitted by Galapagos NV (not Lakefront Biotherapeutics NV as indicated in metadata) for the month of October 2016. The registrant is a foreign private issuer based in Mechelen, Belgium, filing under Rule 13a-16 of the Securities Exchange Act of 1934. The report incorporates a press release dated October 27, 2016, and a Q3 2016 report by reference.

Key Financial Metrics

The provided filing text serves as a cover document and does not contain specific financial data. Consequently, values for revenue, profit, cash flow, margins, debt, and liquidity are not present in this excerpt. The filing references a Q3 2016 report (Exhibit 99.2) where such metrics would be detailed, but the text of that report is not included here.

Material Changes

The filing text does not provide specific details regarding material changes versus prior periods. It solely announces the issuance of a press release and the availability of the Q3 2016 report.

Guidance, Outlook, and Risks

Management commentary, guidance, outlook, risks, contingencies, and unusual items are not described in the cover text of this Form 6-K. These elements are expected to be contained within the attached press release (Exhibit 99.1) and the Q3 2016 report (Exhibit 99.2), which are incorporated by reference but not reproduced in the input.

Investor Verification Checklist

  • Verify the correct registrant name is Galapagos NV, not Lakefront Biotherapeutics NV.
  • Review Exhibit 99.1 (Press Release dated Oct 27, 2016) for specific operational updates or announcements.
  • Consult Exhibit 99.2 (Q3 Report 2016) for actual financial figures, cash flow, and liquidity status.
  • Confirm the filing date of November 9, 2016, and the signature by Xavier Maes, Company Secretary.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.